About ibandrona te
Bisphosphonate bone-resorption inhibitor
Used for
- Prevention of skeletal complications in adults with breast cancer that has spread to bone.
- Treatment of high blood calcium caused by cancer.
Usual adult dose
For breast cancer bone disease: 6 mg intravenously every 3–4 weeks. For cancer-related high calcium: 2–4 mg intravenously once.
Common side effects
- Fever, flu-like symptoms, or chills
- Nausea, vomiting, or diarrhea
- Low blood calcium
- Muscle or joint pain
Important warnings
- Given by intravenous infusion; kidney function and calcium should be monitored.
- Correct low calcium and vitamin D deficiency before treatment.
- Rare risks include jawbone damage and unusual thigh-bone fractures.
- Seek urgent care for severe allergic reactions or breathing problems.
Pregnancy
Avoid during pregnancy; human safety information is limited, and fetal harm is possible.
Breastfeeding
Breastfeeding is not recommended during treatment; whether the medicine passes into breast milk is unknown.
Interactions
- Other kidney-damaging medicines may increase kidney injury risk.
- Calcium supplements and antacids can affect absorption of oral ibandronate; this injection avoids that interaction.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.